SCHEMBL3117396

SCHEMBL3117396

CCCc1c(C(=O)NC2CC2)nnn1-c1ccc(NC(=O)c2ccccc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK1 Q13464 1/20 0.54
▸ POLB P06746 2/20 0.47
▸ TP53 P04637 2/20 0.45
▸ MAPT P10636 7/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ MEN1 O00255 3/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ USP2 O75604 1/20 0.44
▸ RAB9A P51151 3/20 0.43
▸ NPC1 O15118 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ PKM P14618 1/20 0.43
▸ NFKB1 P19838 1/20 0.43
▸ NFKB2 Q00653 1/20 0.43
▸ RELA Q04206 1/20 0.43
▸ HDAC3 O15379 1/20 0.42
▸ HDAC1 Q13547 1/20 0.42
▸ HDAC2 Q92769 1/20 0.42
▸ NCOR2 Q9Y618 1/20 0.42
▸ RIPK1 Q13546 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3115740 0.91 ROCK1 (0.52) ROCK1POLBTP53MAPTALDH1A1
SCHEMBL5243957 0.90 ROCK1 (0.46) ROCK1MAPTMEN1KMT2ARAB9A
SCHEMBL3109517 0.90 ROCK1 (0.46) ROCK1TP53MAPTALDH1A1MEN1
SCHEMBL3104989 0.89 LMNA (0.50) ROCK1POLBTP53MAPTALDH1A1
SCHEMBL3099742 0.88 ROCK1 (0.48) ROCK1POLBTP53MAPTALDH1A1
SCHEMBL3105220 0.88 RAB9A (0.46) ROCK1MAPTKMT2ARAB9ANPC1
SCHEMBL3117945 0.87 ROCK1 (0.48) ROCK1POLBTP53MAPTALDH1A1
SCHEMBL3108685 0.87 ROCK1 (0.47) ROCK1POLBTP53MAPTALDH1A1
SCHEMBL3107465 0.87 ROCK1 (0.47) ROCK1POLBTP53MAPTALDH1A1
SCHEMBL3106964 0.86 ROCK1 (0.50) ROCK1POLBMAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 — — US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 — — US disclosed
EP-1867331-A1 TRIAZOLE DERIVATIVE AND THE USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-12-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105253-A1 Triazole Derivative and Use Thereof F2R, HRH4, F2RL3 ROCK1 1430/4885POLB 3558/4885TP53 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback